Indication
Enteropathy-associated T-cell lymphoma
2 clinical trials
2 products
Clinical trial
Phase 2 Study of Brentuximab Vedotin Associated With CHP Followed by Consolidation With High-dose Therapy / Autologous Stem-cell Transplantation as Frontline Treatment of Patients With Enteropathy-associated T-cell Lymphoma Type 1.Status: Completed, Estimated PCD: 2022-11-21
Product
Brentuximab VedotinClinical trial
A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)Status: Recruiting, Estimated PCD: 2024-06-15
Product
Brentuximab vedotin